Cordlife is Asia’s largest network of cord blood banks

Cordlife celebrates 25 years (in 2026) in business as the largest cord blood banking network in Asia

Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, owns and operates Asia’s largest network of private cord blood banks. The Group is committed to ensuring the health and well-being of both mother and child, amongst others. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia.

Cordlife has processed and stored inventory of more than half a million cord blood, cord lining, cord tissue, and placenta stem cell samples, and has extensive transplant experience. With full stem cell banking facilities in seven key countries, Cordlife is a market leader in Hong Kong, Indonesia and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, StemLife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai StemLife. In addition to cord blood, cord lining, cord tissue, and placenta banking, Cordlife offers families a comprehensive suite of clinical diagnostics, including non-invasive prenatal testing, and newborn metabolic screening. 

Cordlife strives to ensure reliable quality and is committed to a customer-centric approach. For more information, visit https://cordlife.listedcompany.com/.

Cordlife has transplant experience across Asia

<Click on the poster below to view it full size.>

Cordlife Group has made 85 cord blood releases to 25 healthcare institutions in ten different countries, allowing their clients to use their cord blood for transplantation or cellular therapy. Out of these 85 releases, 50 were children using their own (autologous) cord blood, and 35 were children using (allogeneic) cord blood from a donor or sibling.

Cordlife has also assisted its clients in the release of 37 samples of cord lining or cord tissue or mesenchymal stromal cells (MSC) from cord tissue.

All of the samples processed and stored by Cordlife were used successfully in cellular therapy, which is the ultimate validation of the Group’s processing and storage capabilities. 

Over the years, the Group has also grown to offer diagnostics and other healthcare services. This has helped to strengthen their position as a leading company focused on protecting the health of mother and child.